Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEXIDARTINIB Cause Aspartate aminotransferase increased? 134 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 134 reports of Aspartate aminotransferase increased have been filed in association with PEXIDARTINIB (Turalio). This represents 13.8% of all adverse event reports for PEXIDARTINIB.

134
Reports of Aspartate aminotransferase increased with PEXIDARTINIB
13.8%
of all PEXIDARTINIB reports
3
Deaths
21
Hospitalizations

How Dangerous Is Aspartate aminotransferase increased From PEXIDARTINIB?

Of the 134 reports, 3 (2.2%) resulted in death, 21 (15.7%) required hospitalization.

Is Aspartate aminotransferase increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PEXIDARTINIB. However, 134 reports have been filed with the FAERS database.

What Other Side Effects Does PEXIDARTINIB Cause?

Fatigue (378) Product dose omission issue (335) Hair colour changes (327) Nausea (213) Pruritus (186) Rash (131) Off label use (130) Alanine aminotransferase increased (124) Diarrhoea (106) Headache (103)

What Other Drugs Cause Aspartate aminotransferase increased?

METHOTREXATE (1,600) RITUXIMAB (1,351) ADALIMUMAB (1,166) TOCILIZUMAB (975) ETANERCEPT (939) ACETAMINOPHEN (865) LEFLUNOMIDE (863) INFLIXIMAB (823) ABATACEPT (778) NIVOLUMAB (758)

Which PEXIDARTINIB Alternatives Have Lower Aspartate aminotransferase increased Risk?

PEXIDARTINIB vs PHENACETIN PEXIDARTINIB vs PHENAZOPYRIDINE PEXIDARTINIB vs PHENCYCLIDINE PEXIDARTINIB vs PHENELZINE PEXIDARTINIB vs PHENOBARBITAL

Related Pages

PEXIDARTINIB Full Profile All Aspartate aminotransferase increased Reports All Drugs Causing Aspartate aminotransferase increased PEXIDARTINIB Demographics